Drug Discovery@nature.com 04 October 2013

Advertisement Revitalize Your Phenotypic Screens with iCell® Human Cells! Highly pure human iPSC-derived cells. Amenable to use on HTS platforms. Conducive to transient transfection for gene delivery or modulation. Induced and innate disease modeling with MyCell® Products. Easy-to-use kits: iCell Cardiomyocytes, iCell Endothelial Cells, iCell Hepatocytes, iCell Neurons, and more. TABLE OF CONTENTS 4 October 2013 News Analysis Research Highlights Research & Reviews Careers Advertisement   Frontiers in Pharmacology benefits from an innovative peer review process that guarantees the most accurate, efficient and impartial reviews in academic publishing, with genuinely collaborative interactions between authors and referees. "Frontiers has a new model for academic publications...instead of rejecting, we want to help the scientific community to improve their paper" Idan Segev, The Hebrew University of Jerusalem  Nature Reviews Drug Discovery is on Twitter Advertisement SciBX is pleased to present: SciBX Summit on Innovation in Drug Discovery and Development 2013 October 29-30, 2013 The Colonnade Hotel, Boston, MA, USA Click here for more information or to register for this conference today!   News Top PARP inhibitors bounce back doi:10.1038/nrd4147 A series of setbacks almost caused the demise of PARP inhibitors, but four companies are now beginning pivotal trials of these agents in breast and ovarian cancer. Full Text Deal watch: AstraZeneca bets on FibroGen's anaemia drug doi:10.1038/nrd4135 AstraZeneca and FibroGen are to co-develop FG-4592, a small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor that could become a first-in-class treatment option for the treatment of anaemia in patients with chronic kidney disease. Full Text Market watch: Upcoming market catalysts in Q4 2013 doi:10.1038/nrd4136 Notable market catalysts include an FDA advisory panel meeting for tasimelteon for non-24-hour sleep-wake disorder and an FDA decision on the approval of obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia. Full Text India's patent ecosystem - encouraging strong patents or discouraging innovation? doi:10.1038/nrd4139 India has recently rejected or revoked several patents that protect drugs which have patent protection in many other countries. Does this indicate that India's patent system is weak or is it is well placed to weed out weak patents at an early stage? Full Text Analysis Top Anti-CD20 therapy for heart attack doi:10.1038/scibx.2013.1015 A multinational team has used anti-CD20 mAbs to treat heart attacks by depleting inflammation-causing CD20+ B cells at the infarct site. The researchers are planning a Phase IIa trial of Rituxan in MI, and at least one biotech with an anti-CD20 antibody is discussing the findings with its pharma partner. Full Text Pharmaceutical forecasting: throwing darts? doi:10.1038/nrd4127 Forecasting of the future commercial value of drugs is a crucial activity that affects many decisions by pharmaceutical companies. However, this analysis indicates that many forecasts are wrong, often substantially. Full Text Research Highlights Top Anticancer drugs: Stapled peptide reactivates p53 doi:10.1038/nrd4133 The stapled α-helical peptide ATSP-7041 - which is a specific dual inhibitor of MDM2 and MDMX - effectively induces p53-dependent apoptosis and inhibits cell proliferation in mouse models of human tumours. Full Text Biotechnology: Rice-derived rotavirus antibody shows promise doi:10.1038/nrd4131 Researchers have genetically engineered rice to produce high yields of a rotavirus-specific antibody fragment in the seeds. This antibody was effective in treating and preventing rotavirus-induced gastrointestinal symptoms in mice. Full Text Neurodegenerative diseases: New kinase targets for Alzheimer's disease doi:10.1038/nrd4132 Two recent studies show that inhibiting kinases involved in the regulation of amyloid precursor protein processing or protein synthesis by eukaryotic translation initiation factor 2α attenuates disease progression in mice. Full Text Research & Reviews Top Considerations for the successful co-development of targeted cancer therapies and companion diagnostics doi:10.1038/nrd4101 The authors discuss issues relating to the co-development of targeted cancer therapies and companion diagnostics that were not covered in depth in the draft guidance released by the US FDA in 2011. They also propose potential strategies that will be useful to mitigate challenges and to help guide the future co-development of drugs and diagnostics. Full Text Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology doi:10.1038/nrc3580 Anaplastic lymphoma kinase (ALK) is commonly altered - through mutation, overexpression or translocation - in many types of cancer, but the role of ALK signalling in mammalian cells and tumours remains enigmatic. What can we learn from model systems? And what progress has been made in targeting this receptor tyrosine kinase? Full Text p11 and its role in depression and therapeutic responses to antidepressants doi:10.1038/nrn3564 Recent studies have shown that the protein p11 (also known as S100A10) has an important role in depression-like behaviour and antidepressant actions. Greengard and colleagues discuss the molecular and cellular mechanisms that may underlie this role. Full Text Macrophages in atherosclerosis: a dynamic balance doi:10.1038/nri3520 In this Review, the authors provide a comprehensive overview of the role of macrophage dynamics in determining the initiation, progression and regression of atherosclerotic inflammation. Understanding the factors that determine the inflammatory state of the plaque may help to identify potential therapeutic targets for plaque regression. Full Text Drug Discovery JOBS of the week OCE Postdoctoral Fellowship Ocular Drug Delivery CSIRO (Commonwealth Scientific & Industrial Research Organisation) Postdoc Fellow– Drug / siRNA delivery nanoparticle-Polymer Chemistry–Molecular Biology University of Hawaii at Hilo, The Daniel K. Inouye College of Pharmacy PhD fellowship with focus on genetic interactions in response to drug treatment Technical University of Denmark (DTU) Research Associate in Multifunctional Nanoparticles for Simultaneous Imaging and Drug Delivery University College London (UCL) Drug Discovery Opportunities at D. E. Shaw Research D. E. Shaw Research More Science jobs from Drug Discovery EVENT The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease 09.05.14 New York, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.